Patient P-02334

Synthetic patientMETA-24 · Day 156 · 45–54 · M · baseline S04Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Stable

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

51%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S04
Day 75 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 122 GI-04 recommended — GI Support Protocol GI-04
Day 123 Patient accepted — Started GI-04 in the companion
Day 131 GI symptom burden −16% vs expected — GI Support Protocol GI-04
Day 137 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 75.

Primary contributors, last 14 days

Treatment adherence-12
Inflammatory activity-10
Nutritional resilience-7
GI instability-3
Toxicity-2

What helped?

GI Support Protocol GI-04Day 122
Result: symptom burden −16%

LIFE OS recommendation

Monitoring Escalation ME-01

72%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

73 min

stable · +0.8 vs previous 14 d

Sleep duration

Wearable

6.3 h

worsening · -0.3 vs previous 14 d

Energy level

Daily log

3.5/10

worsening · -0.4 vs previous 14 d

Steps

Wearable

8,113

worsening · -427 vs previous 14 d

GI burden

Companion

52.6/100

stable · -0.2 vs previous 14 d

Adherence

Companion

71.3 %

worsening · -10.8 vs previous 14 d

Sleep quality

Wearable

18.6/100

worsening · -2.5 vs previous 14 d

Glucose, CGM daily mean

CGM

145 mg/dL

stable · +1.9 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 48 from the failing basin, 47 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +19.7
Protein (supports)
perturbation · steering +15.5
Daily walks resumed
perturbation · steering +3.3
Protein
supporter · GI -7.9 next day

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
Histamine load
perturbation · steering -13.1
Ultra-processed food
perturbation · steering -12.7
Simple carbohydrates
perturbation · steering -11.5
Histamine load
detractor · GI +6.5 next day
Dietary fat load
detractor · GI +6.2 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-7.9supporter · 95%
Histamine load
+6.5detractor · 95%
Dietary fat load
+6.2detractor · 95%
Simple carbohydrates
+6.1detractor · 95%
Ultra-processed food
+5.9detractor · 95%
Insoluble fibre
-1.8no signal · 27%
Alcohol
+0.4no signal · 15%
Caffeine
-0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
- WearableHRV 15 ms, trending down
Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓45
- WearableResting HR 80 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 52

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 1.9 · butyrate capacity 40/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 6.9 h
Steps: 7,365
Resting HR: 81 bpm

Daily log: GI score 53, nutritional resilience 37, adherence 71.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02054	40%	S01	CR-01	improved	57
P-02409	35%	S01	SC-12	no change	54
P-02018	30%	S01	GI-04	improved	46
P-02410	29%	S01	GI-04	improved	55
P-02307	27%	S01	—	—	55
P-02598	27%	S01	—	—	53
P-02550	26%	S01	—	—	70
P-02276	24%	S01	—	—	57
P-02138	23%	S01	—	—	79
P-02354	23%	S01	CR-01	improved	78
P-02437	23%	S01	—	—	64
P-02568	23%	S01	—	—	51